Literature DB >> 24009237

Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival.

Mark Lambie1, James Chess, Kieron L Donovan, Yong Lim Kim, Jun Young Do, Hi Bahl Lee, Hyunjin Noh, Paul F Williams, Andrew J Williams, Sara Davison, Marc Dorval, Angela Summers, John D Williams, John Bankart, Simon J Davies, Nicholas Topley.   

Abstract

Systemic inflammation, as evidenced by elevated inflammatory cytokines, is a feature of advanced renal failure and predicts worse survival. Dialysate IL-6 concentrations associate with variability in peritoneal small solute transport rate (PSTR), which has also been linked to patient survival. Here, we determined the link between systemic and intraperitoneal inflammation with regards to peritoneal membrane function and patient survival as part of the Global Fluid Study, a multinational, multicenter, prospective, combined incident and prevalent cohort study (n=959 patients) with up to 8 years of follow-up. Data collected included patient demographic characteristics, comorbidity, modality, dialysis prescription, and peritoneal membrane function. Dialysate and plasma cytokines were measured by electrochemiluminescence. A total of 426 survival endpoints occurred in 559 incident and 358 prevalent patients from 10 centers in Korea, Canada, and the United Kingdom. On patient entry to the study, systemic and intraperitoneal cytokine networks were dissociated, with evidence of local cytokine production within the peritoneum. After adjustment for multiple covariates, systemic inflammation was associated with age and comorbidity and independently predicted patient survival in both incident and prevalent cohorts. In contrast, intraperitoneal inflammation was the most important determinant of PSTR but did not affect survival. In prevalent patients, the relationship between local inflammation and membrane function persisted but did not account for an increased mortality associated with faster PSTR. These data suggest that systemic and local intraperitoneal inflammation reflect distinct processes and consequences in patients treated with peritoneal dialysis, so their prevention may require different therapeutic approaches; the significance of intraperitoneal inflammation requires further elucidation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24009237      PMCID: PMC3839554          DOI: 10.1681/ASN.2013030314

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  33 in total

1.  Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients.

Authors:  Simon J Davies
Journal:  Kidney Int       Date:  2004-12       Impact factor: 10.612

2.  A prospective study of peritoneal transport in CAPD patients.

Authors:  D G Struijk; R T Krediet; G C Koomen; E W Boeschoten; F J Hoek; L Arisz
Journal:  Kidney Int       Date:  1994-06       Impact factor: 10.612

3.  Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival.

Authors:  Simon J Davies; Louise Phillips; Patrick F Naish; Gavin I Russell
Journal:  Nephrol Dial Transplant       Date:  2002-06       Impact factor: 5.992

4.  A three-pore model of peritoneal transport.

Authors:  B Rippe
Journal:  Perit Dial Int       Date:  1993       Impact factor: 1.756

5.  Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis.

Authors:  S J Davies; J Bryan; L Phillips; G I Russell
Journal:  Nephrol Dial Transplant       Date:  1996-03       Impact factor: 5.992

6.  Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients.

Authors:  Sung Hee Chung; Olof Heimbürger; Peter Stenvinkel; Abdul Rashid Qureshi; Bengt Lindholm
Journal:  Nephrol Dial Transplant       Date:  2003-03       Impact factor: 5.992

7.  A comparison of peritoneal equilibration tests performed 1 and 4 weeks after PD commencement.

Authors:  David W Johnson; David W Mudge; Sophie Blizzard; Mary Arndt; Amanda O'Shea; Rhonda Watt; Jan Hamilton; Sharon Cottingham; Nicole M Isbel; Carmel M Hawley
Journal:  Perit Dial Int       Date:  2004 Sep-Oct       Impact factor: 1.756

8.  Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1 beta and TNF alpha.

Authors:  N Topley; A Jörres; W Luttmann; M M Petersen; M J Lang; K H Thierauch; C Müller; G A Coles; M Davies; J D Williams
Journal:  Kidney Int       Date:  1993-01       Impact factor: 10.612

9.  Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD.

Authors:  D Zemel; A L Imholz; D R de Waart; C Dinkla; D G Struijk; R T Krediet
Journal:  Kidney Int       Date:  1994-11       Impact factor: 10.612

10.  Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients.

Authors:  Markus Rumpsfeld; Stephen P McDonald; David M Purdie; John Collins; David W Johnson
Journal:  Am J Kidney Dis       Date:  2004-03       Impact factor: 8.860

View more
  50 in total

Review 1.  Genetic Polymorphisms and Peritoneal Membrane Function.

Authors:  Imad Siddique; K Scott Brimble; Louise Walkin; Angela Summers; Paul Brenchley; Sarah Herrick; Peter J Margetts
Journal:  Perit Dial Int       Date:  2014-11-13       Impact factor: 1.756

2.  Editor's introduction--genetic polymorphisms and clinical heterogeneities.

Authors:  Martin Wilkie
Journal:  Perit Dial Int       Date:  2015 Sep-Oct       Impact factor: 1.756

3.  Toll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysis-Associated Fibrosis.

Authors:  Anne-Catherine Raby; Chantal S Colmont; Ann Kift-Morgan; Jörg Köhl; Matthias Eberl; Donald Fraser; Nicholas Topley; Mario O Labéta
Journal:  J Am Soc Nephrol       Date:  2016-07-18       Impact factor: 10.121

4.  The NLRP3 Inflammasome Has a Critical Role in Peritoneal Dialysis-Related Peritonitis.

Authors:  Nicolas Hautem; Johann Morelle; Amadou Sow; Cyril Corbet; Olivier Feron; Eric Goffin; François Huaux; Olivier Devuyst
Journal:  J Am Soc Nephrol       Date:  2017-02-13       Impact factor: 10.121

5.  Cholecalciferol supplementation increases FGF23 in peritoneal dialysis patients with hypovitaminosis D: a randomized clinical trial.

Authors:  Juan C Ramirez-Sandoval; Mauricio Arvizu-Hernandez; Cristino Cruz; Barbara Vazquez-Cantu; Luis J Rojas-Concha; Luis Tamez; Fagundo Reynerio; F Enrique Gomez; Ricardo Correa-Rotter
Journal:  J Nephrol       Date:  2019-03-19       Impact factor: 3.902

6.  A Patient on Peritoneal Dialysis with Refractory Volume Overload.

Authors:  Martin Wilkie
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 8.237

Review 7.  Is there an end in sight for encapsulating peritoneal sclerosis?

Authors:  Klara Paudel; Stanley L Fan
Journal:  Perit Dial Int       Date:  2014 Sep-Oct       Impact factor: 1.756

Review 8.  The Current State of Peritoneal Dialysis.

Authors:  Rajnish Mehrotra; Olivier Devuyst; Simon J Davies; David W Johnson
Journal:  J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 10.121

9.  Peritoneal Equilibration Test and Patient Outcomes.

Authors:  Rajnish Mehrotra; Vanessa Ravel; Elani Streja; Sooraj Kuttykrishnan; Scott V Adams; Ronit Katz; Miklos Z Molnar; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2015-10-13       Impact factor: 8.237

10.  NRF2 and NF-κB mRNA expression in chronic kidney disease: a focus on nondialysis patients.

Authors:  Viviane O Leal; Juliana F Saldanha; Milena B Stockler-Pinto; Ludmila F M F Cardozo; Felipe R Santos; Alex S D Albuquerque; Maurilo Leite; Denise Mafra
Journal:  Int Urol Nephrol       Date:  2015-10-22       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.